135 related articles for article (PubMed ID: 16138006)
1. A phase II study of perifosine in androgen independent prostate cancer.
Posadas EM; Gulley J; Arlen PM; Trout A; Parnes HL; Wright J; Lee MJ; Chung EJ; Trepel JB; Sparreboom A; Chen C; Jones E; Steinberg SM; Daniels A; Figg WD; Dahut WL
Cancer Biol Ther; 2005 Oct; 4(10):1133-7. PubMed ID: 16138006
[TBL] [Abstract][Full Text] [Related]
2. A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms.
Figg WD; Monga M; Headlee D; Shah A; Chau CH; Peer C; Messman R; Elsayed YA; Murgo AJ; Melillo G; Ryan QC; Kalnitskiy M; Senderowicz AM; Hollingshead M; Arbuck SG; Sausville EA
Cancer Chemother Pharmacol; 2014 Nov; 74(5):955-67. PubMed ID: 25183650
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer.
Argiris A; Cohen E; Karrison T; Esparaz B; Mauer A; Ansari R; Wong S; Lu Y; Pins M; Dancey J; Vokes E
Cancer Biol Ther; 2006 Jul; 5(7):766-70. PubMed ID: 16760642
[TBL] [Abstract][Full Text] [Related]
4. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial.
Chee KG; Longmate J; Quinn DI; Chatta G; Pinski J; Twardowski P; Pan CX; Cambio A; Evans CP; Gandara DR; Lara PN
Clin Genitourin Cancer; 2007 Dec; 5(7):433-7. PubMed ID: 18272025
[TBL] [Abstract][Full Text] [Related]
5. A phase II clinical trial of sorafenib in androgen-independent prostate cancer.
Dahut WL; Scripture C; Posadas E; Jain L; Gulley JL; Arlen PM; Wright JJ; Yu Y; Cao L; Steinberg SM; Aragon-Ching JB; Venitz J; Jones E; Chen CC; Figg WD
Clin Cancer Res; 2008 Jan; 14(1):209-14. PubMed ID: 18172272
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma.
Bailey HH; Mahoney MR; Ettinger DS; Maples WJ; Fracasso PM; Traynor AM; Erlichman C; Okuno SH
Cancer; 2006 Nov; 107(10):2462-7. PubMed ID: 17058289
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of paclitaxel/doxorubicin/ thalidomide in patients with androgen- independent prostate cancer.
Amato RJ; Sarao H
Clin Genitourin Cancer; 2006 Mar; 4(4):281-6. PubMed ID: 16729912
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours.
Vink SR; Schellens JH; Beijnen JH; Sindermann H; Engel J; Dubbelman R; Moppi G; Hillebrand MJ; Bartelink H; Verheij M
Radiother Oncol; 2006 Aug; 80(2):207-13. PubMed ID: 16914220
[TBL] [Abstract][Full Text] [Related]
9. In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines.
Dasmahapatra GP; Didolkar P; Alley MC; Ghosh S; Sausville EA; Roy KK
Clin Cancer Res; 2004 Aug; 10(15):5242-52. PubMed ID: 15297428
[TBL] [Abstract][Full Text] [Related]
10. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM
Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial.
Knowling M; Blackstein M; Tozer R; Bramwell V; Dancey J; Dore N; Matthews S; Eisenhauer E
Invest New Drugs; 2006 Sep; 24(5):435-9. PubMed ID: 16528479
[TBL] [Abstract][Full Text] [Related]
12. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
Sinibaldi VJ; Carducci MA; Moore-Cooper S; Laufer M; Zahurak M; Eisenberger MA
Cancer; 2002 Mar; 94(5):1457-65. PubMed ID: 11920502
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome.
Gojo I; Perl A; Luger S; Baer MR; Norsworthy KJ; Bauer KS; Tidwell M; Fleckinger S; Carroll M; Sausville EA
Invest New Drugs; 2013 Oct; 31(5):1217-27. PubMed ID: 23443507
[TBL] [Abstract][Full Text] [Related]
14. Vinorelbine in androgen-independent metastatic prostatic carcinoma--a phase II study.
Morant R; Hsu Schmitz SF; Bernhard J; Thürlimann B; Borner M; Wernli M; Egli F; Forrer P; Streit A; Jacky E; Hanselmann S; Bauer J; Hering F; Schmid HP
Eur J Cancer; 2002 Aug; 38(12):1626-32. PubMed ID: 12142053
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors.
Becher OJ; Millard NE; Modak S; Kushner BH; Haque S; Spasojevic I; Trippett TM; Gilheeney SW; Khakoo Y; Lyden DC; De Braganca KC; Kolesar JM; Huse JT; Kramer K; Cheung NV; Dunkel IJ
PLoS One; 2017; 12(6):e0178593. PubMed ID: 28582410
[TBL] [Abstract][Full Text] [Related]
16. First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours.
Unger C; Berdel W; Hanauske AR; Sindermann H; Engel J; Mross K
Eur J Cancer; 2010 Mar; 46(5):920-5. PubMed ID: 20079628
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours.
Crul M; Rosing H; de Klerk GJ; Dubbelman R; Traiser M; Reichert S; Knebel NG; Schellens JH; Beijnen JH; ten Bokkel Huinink WW
Eur J Cancer; 2002 Aug; 38(12):1615-21. PubMed ID: 12142051
[TBL] [Abstract][Full Text] [Related]
18. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer.
Harris KA; Weinberg V; Bok RA; Kakefuda M; Small EJ
J Urol; 2002 Aug; 168(2):542-5. PubMed ID: 12131305
[TBL] [Abstract][Full Text] [Related]
19. A Phase 2 study of perifosine in advanced or metastatic breast cancer.
Leighl NB; Dent S; Clemons M; Vandenberg TA; Tozer R; Warr DG; Crump RM; Hedley D; Pond GR; Dancey JE; Moore MJ
Breast Cancer Res Treat; 2008 Mar; 108(1):87-92. PubMed ID: 17458693
[TBL] [Abstract][Full Text] [Related]
20. Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in patients with prostate cancer.
Boccon-Gibod L; Albers P; Morote J; van Poppel H; de la Rosette J; Villers A; Malmberg A; Neijber A; Montorsi F
Eur Urol; 2014 Oct; 66(4):655-63. PubMed ID: 24954791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
